Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07431281 · ClinicalTrials.gov registry record · Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
A Phase 3 study of Gastric Cancer and Esophageal Cancer, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 2,130
- Enrollment target
- 20
- Study locations
NCT07431281: Recruiting Phase 3 study of Gastric Cancer and Esophageal Cancer, sponsored by AstraZeneca.
NCT07431281 is a Phase 3 study of Gastric Cancer and Esophageal Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 2,130 participants, above the 305-participant average among 153 other Gastric Cancer trials with a reported enrollment target (598% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07431281, a Phase 3 study of Gastric Cancer and Esophageal Cancer, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 2,130 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma.
Primary Outcome
PFS is defined as time from randomisation until progression per RECIST 1.1, or death due to any cause, whichever occurs first.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Nivolumab
- DRUG 5-Fluorouracil
- DRUG Rilvegostomig
- DRUG Sonesitatug vedotin
Study Locations (20)
California
- Research Site - Duarte
- Research Site - La Jolla
- Research Site - Orange
- Research Site - Walnut Creek
Florida
- Research Site - Fort Myers
- Research Site - Jacksonville
- Research Site - St. Petersburg
- Research Site - West Palm Beach
Georgia
- Research Site - Atlanta
- Research Site - Atlanta
- Research Site - Atlanta
Illinois
- Research Site - Chicago
- Research Site - Niles
Kentucky
- Research Site - Lexington
- Research Site - Louisville
Arizona
- Research Site - Phoenix
Colorado
- Research Site - Lone Tree
Connecticut
- Research Site - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,130 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2031-10-27 |
| Phase | Phase 3 |
What NCT07431281 shows while recruiting
NCT07431281 is an interventional study that assigns participants to a tested intervention. Its 2,130 participants enrollment target places it among the larger protocols in the corpus, above the 305-participant average among 153 other Gastric Cancer trials with a reported enrollment target (598% higher).
The record links to 3 conditions, with Gastric Cancer appearing as the primary indexed condition, and to 5 interventions - of which Capecitabine is the first listed.
NCT07431281 names 20 study sites across 10 states, led by California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT07431281 about?
NCT07431281 is a clinical study titled "Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2". The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor receptor 2 (HER2)-negative, gastric, gastroesophageal junction (GEJ...
What is the current status of trial NCT07431281?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 2,130 participants. The study started on 2026-02-03. Estimated completion is 2031-10-27.
What conditions does trial NCT07431281 study?
This clinical trial studies the following conditions: Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma.
What interventions are being tested in trial NCT07431281?
The interventions under investigation include: Capecitabine (DRUG), Nivolumab (DRUG), 5-Fluorouracil (DRUG), Rilvegostomig (DRUG), Sonesitatug vedotin (DRUG).
Who is sponsoring clinical trial NCT07431281?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07431281 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07431281's enrollment target sits among peer trials
2,130 5th of 153 higher than 149 of 153 other Gastric Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Gastric Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
RECRUITING · Phase 3
-
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
RECRUITING · Phase 3
-
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
RECRUITING · Phase 3
-
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
ACTIVE NOT RECRUITING · Phase 3
-
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
ACTIVE NOT RECRUITING · Phase 3
-
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05650658 · 2,136 participants · NA
Left vs Left Randomized Clinical Trial
- NCT05681624 · 2,124 participants · NA
Maternal Oxygen Supplementation for Intrauterine Resuscitation
- NCT03488693 · 2,140 participants · Phase 3
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
- NCT05916430 · 2,120 participants
Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI